Furthermore, we detected a mismatch between the tumor cellularity and the allelic ratio of the KRAS G12C mutation in 24.3% of cases, suggesting that, at the cellular level, the mutation is heterogeneously present among tumor cells. Here, KRAS is linked to neoplasm.